Ivy Brain Tumor Center

Birmingham, Alabama

Oncologysmall moleculePhase III

What changed

Phase III trial registered: A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

2w agoTrial registeredJul 1, 2026Source filing (opens the source filing in a new tab)

Momentum

88no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
Study registered
Sep 1, 2026
Ovarian Cancer, Antibody-drug Conjugates, Clear Cell Adenocarcinoma of Ovary · NOT_YET_RECRUITING · sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
ClinicalTrials.gov · NCT07168083 (opens the source filing in a new tab)
Grant
R21 · $409k · non-dilutive
Mar 13, 2026
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, JING · NCI · award ends Feb 29, 2028 · Immunosuppression mediated by regulatory CD8+ T cells in lung cancers
NIH RePORTER · NIH RePORTER 11303011 (opens the source filing in a new tab)
Grant
R35 · $383k · non-dilutive
Aug 15, 2025
UNIVERSITY OF MISSISSIPPI · PI LI, JING · NIGMS · award ends Jul 31, 2030 · Computational Studies of Molecular Medicine for Voltage-Gated Sodium Channels
NIH RePORTER · NIH RePORTER 11203157 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 19, 2024
Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor · ACTIVE_NOT_RECRUITING · sponsor: Ivy Brain Tumor Center · A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
ClinicalTrials.gov · NCT06388733 (opens the source filing in a new tab)
Trial
NA registered
Jul 1, 2023
Diabetes Mellitus, Constipation - Functional · RECRUITING · sponsor: Peking Union Medical College Hospital · Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients
ClinicalTrials.gov · NCT07065942 (opens the source filing in a new tab)
Grant
R01 · $365k · non-dilutive
Aug 1, 2021
WAYNE STATE UNIVERSITY · PI LI, JING · NCI · award ends Jul 31, 2027 · Physiologically Based Pharmacokinetic Modeling of Drug Penetration into the Human Brain and Brain Tumors
NIH RePORTER · NIH RePORTER 11137026 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 28, 2020
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
ClinicalTrials.gov · NCT04516070 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 2, 2012
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8 · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
ClinicalTrials.gov · NCT01644591 (opens the source filing in a new tab)
Grant
P30 · $146k · non-dilutive
Aug 8, 1997
WAYNE STATE UNIVERSITY · PI LI, JING · NCI · award ends Nov 30, 2026 · Pharmacology and Metabolomics Core (PMC)
NIH RePORTER · NIH RePORTER 11514606 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.28semantic similarity 82% · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
2w agoTrial registeredSource (opens the source filing in a new tab)
NIH P30 · $0.1M · Pharmacology and Metabolomics Core (PMC)
3mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.4M · Immunosuppression mediated by regulatory CD8+ T cells in lung cancers
3mo agoNew grantSource (opens the source filing in a new tab)
Phase II trial registered: Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
4mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
4mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
10mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Computational Studies of Molecular Medicine for Voltage-Gated Sodium Channels
11mo agoNew grantSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Physiologically Based Pharmacokinetic Modeling of Drug Penetration into the Human Brain and Brain Tumors
12mo agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients
Jul 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients
Jul 2025Trial recruitingSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

Study registered

R21 · $409k · non-dilutive

R35 · $383k · non-dilutive

PHASE3 registered

NA registered

R01 · $365k · non-dilutive

PHASE2 registered

PHASE2 registered

P30 · $146k · non-dilutive